Adherence to COVID -19 protective practices in Ethiopia: Use and predictors of face mask-wearing.

COVID-19 Ethiopia face mask personal protective equipment

Journal

Ethiopian medical journal
ISSN: 0014-1755
Titre abrégé: Ethiop Med J
Pays: Ethiopia
ID NLM: 0373223

Informations de publication

Date de publication:
30 Oct 2022
Historique:
medline: 30 10 2022
pubmed: 30 10 2022
entrez: 29 12 2023
Statut: ppublish

Résumé

The Ethiopian Ministry of Health strongly recommends that anyone, regardless of vaccination status, wears a standard face mask consistently when in public. This study aimed to assess the self-reported use and predictors of wearing face masks in the general population in Ethiopia. This was a population-based cross-sectional study using a telephone survey. Adults living in Ethiopia were randomly selected from the Ethio Telecom list of mobile phone numbers and interviewed about their mask-wearing practice and individual and household-level factors that could impact on the use of face masking. Multivariable logistic regression was used to measure associations. A total of 614 participants were interviewed from September to November 2021. The prevalence of self-reported face mask use when in public was 81.1%. Living outside Addis Ababa, including Oromia [adjusted odds ratio [(AOR) 0.30, 95% confidence interval (CI) (0.14, 0.63)], Amhara [AOR 0.11, 95% CI (0.05, 0.23)], and Southern Nations, Nationalities and People's Region [AOR 0.31, 95% CI (0.12-0.79)] and being divorced or widowed [AOR 0.18, 95% CI (0.06, 0.62)] were found to be inversely associated with face mask use. Female gender [AOR 1.91, 95% CI (1.02, 3.58)] and older age [age ≥ 50, AOR 2.96, 95% CI (1.09-7.97)] were positively associated with the use of face masks. Attending social events [AOR 0.51, 95% CI (0.31-0.82)], was negatively associated with the use of face masks. Self-reported use of face masks was relatively high nationally, but inconsistent among different regions and demographics. The findings imply that policies and messaging campaigns may need to focus on specific populations and behaviors in this ongoing pandemic.

Identifiants

pubmed: 38156328
pmc: PMC10753859

Types de publication

Journal Article

Langues

eng

Pagination

48-56

Déclaration de conflit d'intérêts

Declarations Competing interests The authors declare that they have no competing interests.

Auteurs

Hanna Negussie (H)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Sewit Timothewos (S)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Bethelhem Fekadu (B)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Winini Belay (W)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Medhin Selamu (M)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO collaborating center for Mental Health research and capacity building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.

Eyerusalem Getachew (E)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Abigiya Wondimagegnehu (A)

Addis Ababa University, College of Health Sciences, School of Public Health, Addis Ababa, Ethiopia.
Martin-Luther-University, Institute of Medical Epidemiology, Bio statistics and Informatics, Halle, Germany.

Tigist Eshetu (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Rahel Birhane (R)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Tigest Ajeme (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Charlotte Hanlon (C)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO collaborating center for Mental Health research and capacity building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Global Mental Health, London, UK.

Eyasu Makonnen (E)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, College of Health Sciences, Department of Pharmacology and Clinical Pharmacy, Addis Ababa, Ethiopia.

Tsegahun Manyazewal (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Abebaw Fekadu (A)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO collaborating center for Mental Health research and capacity building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.
Brighton and Sussex Medical School, Global Health and Infection Department, Brighton, UK.

Classifications MeSH